Skip to main content
. 2024 Nov 15;16(11):1458. doi: 10.3390/pharmaceutics16111458

Table 3.

Comparison of efficacy and toxicity in [177Lu]Lu and [225Ac]Ac-labeled PSMA for TRT in mCRPC * patients.

[177Lu]Lu-PSMA [225Ac]Ac-PSMA
  • β-emitter with g 113, 208 keV

  • LET 0.5 MeV, 0.2 keV/μm

  • Range 2 mm (crossfire effect)

  • Half-life 6.7 days

  • >50% PSA decline rate of 46% **

  • Adverse event: resistance, sialadenitis, less nephrotoxicity

  • α-emitter with 4a, and g 440 keV

  • LET 5.8 MeV, 100 keV/μm

  • Range 40–100 μm (by-stander effect)

  • Half-life 9.9 days

  • >50% PSA decline rate of 60% **

  • Adverse event: sialadenitis, more nephrotoxicity

* mCRPC: metastatic castration resistant prostate cancer. ** References: [80,81,82].